Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more - 2One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- 36 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- 4Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- 5Iran slams UN nuclear watchdog for failing to condemn Bushehr attacks
- Italy Brings In New Measures In 2026 To Tackle Overtourism
- IVE 2026 'Show What I Am' Tour: How to get tickets, prices, dates and more
- Danish warship sunk by famed British admiral discovered after 225 years
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- FDA proposes use of sunscreen ingredient popular in other countries
- A definitive Handbook for Securities exchange Money management
- Dick Van Dyke shares his secrets to longevity as he turns 100
